Cargando…

Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran

BACKGROUND: Understanding the reasons for loss to follow-up (LTFU) in cohort studies, especially among marginalized groups such as people who inject drugs (PWID), is needed to strengthen the rigor of efficacy trials for prevention and treatment interventions. We assessed the proportion and reasons f...

Descripción completa

Detalles Bibliográficos
Autores principales: Mousavian, Ghazal, Ghalekhani, Nima, Tavakoli, Fatemeh, McFarland, Willi, Shahesmaeili, Armita, Sharafi, Heidar, Khezri, Mehrdad, Mehmandoost, Soheil, Zarei, Jasem, Sharifi, Hamid, Mirzazadeh, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017615/
https://www.ncbi.nlm.nih.gov/pubmed/33794943
http://dx.doi.org/10.1186/s13011-021-00368-9
_version_ 1783674084107747328
author Mousavian, Ghazal
Ghalekhani, Nima
Tavakoli, Fatemeh
McFarland, Willi
Shahesmaeili, Armita
Sharafi, Heidar
Khezri, Mehrdad
Mehmandoost, Soheil
Zarei, Jasem
Sharifi, Hamid
Mirzazadeh, Ali
author_facet Mousavian, Ghazal
Ghalekhani, Nima
Tavakoli, Fatemeh
McFarland, Willi
Shahesmaeili, Armita
Sharafi, Heidar
Khezri, Mehrdad
Mehmandoost, Soheil
Zarei, Jasem
Sharifi, Hamid
Mirzazadeh, Ali
author_sort Mousavian, Ghazal
collection PubMed
description BACKGROUND: Understanding the reasons for loss to follow-up (LTFU) in cohort studies, especially among marginalized groups such as people who inject drugs (PWID), is needed to strengthen the rigor of efficacy trials for prevention and treatment interventions. We assessed the proportion and reasons for loss to follow-up in a recent cohort of PWID enrolled in the southeast of Iran. METHODS: Using respondent-driven sampling, we recruited 98 PWID age 18 years or older who reported injecting drugs in the past 6 months, and were negative for HIV and HCV at initial screening. Participants were followed at 6 week intervals, alternating a short six-week visit and long 12-week or quarterly visit to measure incidence of HIV and HCV. Methods to enhance retention included incentives for completing each visit, tracking people who missed the scheduled visits through their peer referral networks, engaged outreach teams to explore hotspots and residences, and photos. LTFU was defined as participants who missed their quarterly visits for two or more weeks. RESULTS: Mean (SD) age of participants was 39.7 years (SD 9.6). Of 98 enrolled, 50 participants (51.0%) were LTFU by missed their scheduled quarterly visits for 2 weeks or more. For those whose reasons for LTFU could be defined (46.0%, 23 of 50), main reasons were: forgetting the date of visit (43.5%, 10 of 23), being incarcerated (39.1%, 9 of 23), and moving out of the city (17.4%, 4 of 23). CONCLUSION: This study highlighted the difficulty in retaining PWID in longitudinal studies. Despite having several retention strategies in place, over half of PWID were LTFU. The LTFU might be reduced by setting up more effective reminder systems, working closely with security systems, and online means to reach those who move outside the study area.
format Online
Article
Text
id pubmed-8017615
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80176152021-04-02 Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran Mousavian, Ghazal Ghalekhani, Nima Tavakoli, Fatemeh McFarland, Willi Shahesmaeili, Armita Sharafi, Heidar Khezri, Mehrdad Mehmandoost, Soheil Zarei, Jasem Sharifi, Hamid Mirzazadeh, Ali Subst Abuse Treat Prev Policy Research BACKGROUND: Understanding the reasons for loss to follow-up (LTFU) in cohort studies, especially among marginalized groups such as people who inject drugs (PWID), is needed to strengthen the rigor of efficacy trials for prevention and treatment interventions. We assessed the proportion and reasons for loss to follow-up in a recent cohort of PWID enrolled in the southeast of Iran. METHODS: Using respondent-driven sampling, we recruited 98 PWID age 18 years or older who reported injecting drugs in the past 6 months, and were negative for HIV and HCV at initial screening. Participants were followed at 6 week intervals, alternating a short six-week visit and long 12-week or quarterly visit to measure incidence of HIV and HCV. Methods to enhance retention included incentives for completing each visit, tracking people who missed the scheduled visits through their peer referral networks, engaged outreach teams to explore hotspots and residences, and photos. LTFU was defined as participants who missed their quarterly visits for two or more weeks. RESULTS: Mean (SD) age of participants was 39.7 years (SD 9.6). Of 98 enrolled, 50 participants (51.0%) were LTFU by missed their scheduled quarterly visits for 2 weeks or more. For those whose reasons for LTFU could be defined (46.0%, 23 of 50), main reasons were: forgetting the date of visit (43.5%, 10 of 23), being incarcerated (39.1%, 9 of 23), and moving out of the city (17.4%, 4 of 23). CONCLUSION: This study highlighted the difficulty in retaining PWID in longitudinal studies. Despite having several retention strategies in place, over half of PWID were LTFU. The LTFU might be reduced by setting up more effective reminder systems, working closely with security systems, and online means to reach those who move outside the study area. BioMed Central 2021-04-01 /pmc/articles/PMC8017615/ /pubmed/33794943 http://dx.doi.org/10.1186/s13011-021-00368-9 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Mousavian, Ghazal
Ghalekhani, Nima
Tavakoli, Fatemeh
McFarland, Willi
Shahesmaeili, Armita
Sharafi, Heidar
Khezri, Mehrdad
Mehmandoost, Soheil
Zarei, Jasem
Sharifi, Hamid
Mirzazadeh, Ali
Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran
title Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran
title_full Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran
title_fullStr Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran
title_full_unstemmed Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran
title_short Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran
title_sort proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure hiv and hcv incidence in kerman, iran
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017615/
https://www.ncbi.nlm.nih.gov/pubmed/33794943
http://dx.doi.org/10.1186/s13011-021-00368-9
work_keys_str_mv AT mousavianghazal proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran
AT ghalekhaninima proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran
AT tavakolifatemeh proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran
AT mcfarlandwilli proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran
AT shahesmaeiliarmita proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran
AT sharafiheidar proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran
AT khezrimehrdad proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran
AT mehmandoostsoheil proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran
AT zareijasem proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran
AT sharifihamid proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran
AT mirzazadehali proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran